Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) have received an average rating of “Buy” from the nine brokerages that are covering the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $12.88.

Several analysts recently weighed in on FOLD shares. Zacks Investment Research cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Chardan Capital set a $15.00 target price on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. Leerink Swann restated a “buy” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Tuesday, November 8th. Finally, Cowen and Company restated an “outperform” rating and issued a $15.00 target price on shares of Amicus Therapeutics in a report on Tuesday, November 8th.

Amicus Therapeutics (NASDAQ:FOLD) opened at 8.90 on Friday. The stock has a 50 day moving average price of $7.81 and a 200 day moving average price of $6.95. Amicus Therapeutics has a one year low of $4.98 and a one year high of $11.78. The company’s market cap is $1.27 billion.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.01. The business earned $2.10 million during the quarter, compared to the consensus estimate of $1.71 million. On average, equities analysts anticipate that Amicus Therapeutics will post ($1.38) EPS for the current fiscal year.

In other Amicus Therapeutics news, insider Hung Do sold 25,000 shares of the company’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total value of $175,000.00. Following the completion of the sale, the insider now directly owns 583,453 shares of the company’s stock, valued at approximately $4,084,171. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Daphne Quimi sold 8,546 shares of the company’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $8.00, for a total transaction of $68,368.00. Following the completion of the sale, the senior vice president now directly owns 24,189 shares of the company’s stock, valued at $193,512. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

A number of large investors have recently modified their holdings of FOLD. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Amicus Therapeutics during the second quarter worth about $108,000. Principal Financial Group Inc. increased its stake in shares of Amicus Therapeutics by 10.5% in the second quarter. Principal Financial Group Inc. now owns 22,411 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 2,122 shares during the last quarter. BlackRock Inc. increased its stake in shares of Amicus Therapeutics by 224.8% in the second quarter. BlackRock Inc. now owns 26,443 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 18,301 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Amicus Therapeutics during the third quarter worth about $151,000. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “Amicus Therapeutics Inc. (FOLD) Receives $12.88 Consensus Target Price from Brokerages” was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/28/amicus-therapeutics-inc-fold-receives-12-88-consensus-target-price-from-brokerages.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.